Search Results - "Englund, Simon"
-
1
COVID‐19 clinical outcomes and DMT of MS patients and population‐based controls
Published in Annals of clinical and translational neurology (2022)“…Objective To estimate risks for all‐cause mortality and for severe COVID‐19 in multiple sclerosis patients and across relapsing–remitting multiple sclerosis…”
Get full text
Journal Article -
2
Trajectories of self-reported fatigue following initiation of multiple sclerosis disease-modifying therapy
Published in Journal of neurology, neurosurgery and psychiatry (2024)“…BackgroundWe analysed the COMparison Between All immunoTherapies for Multiple Sclerosis (NCT03193866), a Swedish nationwide observational study in…”
Get full text
Journal Article -
3
Risk of depression in multiple sclerosis across disease-modifying therapies
Published in Multiple sclerosis (01-04-2022)“…Background: Depression and use of antidepressants are more common among patients with multiple sclerosis (MS) compared to the general population, but the…”
Get full text
Journal Article -
4
Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study
Published in Multiple sclerosis (01-05-2023)“…Background: There is a paucity of information on maternal multiple sclerosis (MS) and risk of adverse pregnancy and perinatal outcomes. Objective: The aim of…”
Get full text
Journal Article -
5
Can health behaviours prolong survival and compress the period of survival with the disability? A population-based cohort study
Published in Age and ageing (01-03-2021)“…Abstract Background It remains unclear whether and to what extent health behaviours may prolong survival and compress the period of survival with disability…”
Get full text
Journal Article -
6
Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy
Published in Journal of neurology, neurosurgery and psychiatry (2024)“…BackgroundWe analysed the COMparison Between All immunoTherapies for Multiple Sclerosis (NCT03193866), a Swedish nationwide observational study in…”
Get full text
Journal Article -
7
COMBAT‐MS: A Population‐Based Observational Cohort Study Addressing the Benefit–Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab
Published in Annals of neurology (2024)“…Objective To assess comparative effectiveness, safety, and tolerability of off‐label rituximab, compared with frequently used therapies approved for multiple…”
Get full text
Journal Article -
8
Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden
Published in JAMA network open (01-12-2021)“…This case-control study examines the risk of severe COVID-19 infection in individuals with multiple sclerosis who were receiving rituximab…”
Get full text
Journal Article -
9
Predictors of patient-reported fatigue symptom severity in a nationwide multiple sclerosis cohort
Published in Multiple sclerosis and related disorders (2023)“…•We addressed self-reported fatigue and its association with a number of covariates.•Higher disability stood out as the best predictor of fatigue among…”
Get full text
Journal Article